DOCSLIB.ORG

Atlas Journal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Atlas Journal Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Atlas Journal Atlas Journal versus Atlas Database: the accumulation of the issues of the Journal constitutes the body of the Database/Text-Book. TABLE OF CONTENTS Volume 3, Number 3, Jul-Sep 1999 Previous Issue / Next Issue Genes CBFb (subunit b of core binding factor) (16q22). Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 286-290. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/CBFbID45.html MYH11 (myosin heavy chain) (incomplete) (16p13). Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 291-295. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/MYH11ID43.html PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) (10q23.3). Michel Longy. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 296-300. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/PTENID158.html CBLb (Cas-Br-M (murine) ecotropic retroviral transforming sequence b) (3q). Olivier Rosnet. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 301-3055. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/CBLbID193.html CBLc (Cas-Br-M (murine) ecotropic retroviral transforming sequence c) (19q13.2). Olivier Rosnet. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 306-309. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/CBLcID194.html CBL (Cas-Br-M (murine) ecotropic retroviral transforming sequence) (11q23-q25). Olivier Rosnet. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 310-314. [Full Text] [PDF] Atlas Genet Cytogenet Oncol Haematol 1999; 2 I URL : http://AtlasGeneticsOncology.org/Genes/CBLID171.html HLF (hepatic leukemia factor) (17q22). Franck Viguié. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 315-319. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/HLFID47.html RB1 (retinoblastoma) (13q14). Dietmar R Lohmann. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 320-325. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/RB1ID90.html Leukaemias -7/del(7q) in childhood. François Desangles. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 326-330. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/del7qChildID1152.html -7/del(7q) in adults. François Desangles. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 331-335. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/del7qID1093.html dic(9;20)(p11-13;q11). Barbara Gibbons. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 336-337. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/dic920ID1143.html High hyperdiploid acute lymphoblastic leukaemia. Barbara Gibbons. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 338-340. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/hyperploidID1085.html Severe hypodiploid acute lymphoblastic leukaemia. Barbara Gibbons. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 341-342. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/hypoploidyID1087.html del(16)(q22); inv(16)(p13q22); t(16;16)(p13;q22) - updated. Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 343-348. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/inv16.html Near haploid acute lymphoblastic leukaemia. Barbara Gibbons. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 349-350. [Full Text] [PDF] Atlas Genet Cytogenet Oncol Haematol 1999; 2 II URL : http://AtlasGeneticsOncology.org/Anomalies/nearhaploidID1045.html 9p Rearrangements in ALL. Nyla A Heerema. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 351-353. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/9prearrALLID1156.html t(10;14)(q24;q11); t(7;10)(q34;q24) . Christine Pérot. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 354-357. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/1014ID1068.html t(1;18)(q25;q23). Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 358-359. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Anomalies/t0118ID1162.html Solid Tumours Soft tissue tumors: Desmoplastic small round cell tumor. Christine Pérot. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 360-364. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/desmoplasticID5023.html Eye: Posterior uveal melanoma. Karen Sisley. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 365-368. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/UvealmelanomID5047.html Uterus: Carcinoma of the cervix. Niels B Atkin. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 369-373. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Tumors/CervixUteriID5046.html Cancer Prone Diseases Diamond-Blackfan anemia (DBA). Hope H. Punnett. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 374-375. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Kprones/DiamondBlackfanID10040.html Hyperparathyroidism-Jaw Tumor syndrome (HPT-JT). Maurine R Hobbs. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 376-379. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Kprones/Hyperpar-JawID10052.html Deep Insights Atlas Genet Cytogenet Oncol Haematol 1999; 2 III Minimal residual disease in acute lymphoblastic leukemia. Hélène Cavé. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (3): 380-388. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Deep/MinResidDisID20007.html Case Reports Educational Items © Atlas of Genetics and Cytogenetics in Oncology and Haematology X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching For comments and suggestions or contributions, please contact us [email protected]. Atlas Genet Cytogenet Oncol Haematol 1999; 2 IV Atlas of Genetics and Cytogenetics in Oncology and Haematology NONO Identity Hugo NONO Location Xq12 DNA/RNA Transcription alternative splicing; 2.4 mRNA complete cds; coding sequence: CDS 129 ... 1550 Protein Description the protein encoded by NONO is called p54nrb (nuclear RNA binbing); 471 amino acids; 54 kDa; N-term glutamine/histidine rich region, tandem RNA binding domains (amino acids 75 to 228), helix-turn-helix implicated in DNA binding, and a proline rich region in C-term; N-term and C-term allow protein-protein interactions. Expression wide Function binds independantly to DNA and RNA; forms a heterodimer with PSF, a protein sharing vast homologies; both form complexes with DNA topoisomerase I, which renders this enzyme much more active; NONO also enhances the binding of several DNA-binding proteins (but not all). Homology with PSF and other proteins with a DBHS domain (Drosophila behaviour, human splicing) which includes the tandem RNA binding domains. Implicated in Entity inv(X)(p11.2q12) in renal cell carcinoma -->NonO/TFE3 Disease only one case of papillary renal cell carcinoma Hybrid/Mutated 5' NONO- 3' TFE3 Gene Abnormal N-term NONO and most of it except the C-term proline rich sequence Protein fused to the DNA binding domains of TFE3 (excluding the acidic transcriptional activation domain, including the C-term helix-loop- Atlas Genet Cytogenet Oncol Haematol 1999; 2 -133- helix, and the leucine zipper); the reciprocal transcript is found External links Nomenclature Hugo NONO GDB NONO Entrez_Gene NONO 4841 non-POU domain containing, octamer-binding Cards Atlas NONOID168 GeneCards NONO Ensembl NONO CancerGene NONO Genatlas NONO GeneLynx NONO eGenome NONO euGene 4841 Genomic and cartography NONO - Xq12 chrX:70286488-70304037 + Xq13.1 (hg17- GoldenPath May_2004) Ensembl NONO - Xq13.1 [CytoView] NCBI Genes Cyto Gene Seq [Map View - NCBI] OMIM Disease map [OMIM] HomoloGene NONO Gene and transcription Genbank Y11289 [ SRS ] Y11289 [ ENTREZ ] Genbank AK055406 [ SRS ] AK055406 [ ENTREZ ] Genbank AU119361 [ SRS ] AU119361 [ ENTREZ ] Genbank BC002364 [ SRS ] BC002364 [ ENTREZ ] Genbank BC003129 [ SRS ] BC003129 [ ENTREZ ] RefSeq NM_007363 [ SRS ] NM_007363 [ ENTREZ ] RefSeq NT_086956 [ SRS ] NT_086956 [ ENTREZ ] AceView NONO AceView - NCBI TRASER NONO Traser - Stanford Unigene Hs.533282 [ SRS ] Hs.533282 [ NCBI ] HS533282 [ spliceNest ] Protein : pattern, domain, 3D structure SwissProt Q15233 [ SRS] Q15233 [ EXPASY ] Q15233 [ INTERPRO ] Prosite PS50102 RRM [ SRS ] PS50102 RRM [ Expasy ] Interpro IPR000504 RNA_rec_mot [ SRS ] IPR000504 RNA_rec_mot [ EBI ] Atlas Genet Cytogenet Oncol Haematol 1999; 2 -134- CluSTr Q15233 Pfam PF00076 RRM_1 [ SRS ] PF00076 RRM_1 [ Sanger ] pfam00076 [ NCBI- CDD ] Blocks Q15233 Polymorphism : SNP, mutations, diseases OMIM 300084 [ map ] GENECLINICS 300084 SNP NONO [dbSNP-NCBI] SNP NM_007363 [SNP-NCI] SNP NONO [GeneSNPs - Utah] NONO [SNP - CSHL] NONO] [HGBASE - SRS] General knowledge Family NONO [UCSC Family Browser] Browser SOURCE NM_007363 SMD Hs.533282 SAGE Hs.533282 Amigo function|DNA binding Amigo function|RNA binding Amigo process|RNA splicing Amigo process|mRNA processing Amigo component|nucleus Amigo function|pre-mRNA splicing factor activity BIOCARTA RNA polymerase III transcription PubGene NONO Other databases Probes Probe NONO Related clones (RZPD - Berlin) PubMed PubMed 11 Pubmed reference(s) in LocusLink Bibliography Purification and cDNA cloning of HeLa cell p54nrb, a nuclear protein with two RNA recognition motifs and extensive homology to human splicing factor PSF and Drosophila NONA/BJ6. Dong B, Horowitz DS, Kobayashi R, Krainer AR Nucleic Acids Res
Load more

Recommended publications
  • Renal Cell Carcinoma – Detection of PRCC-TFE3 and Alpha-TFEB Gene Fusions Using RT-PCR on Tissues (Odes 60153 and 60154) Notice of Assessment
    Renal Cell Carcinoma – Detection of PRCC-TFE3 and Alpha-TFEB Gene Fusions Using RT-PCR on Tissues (odes 60153 and 60154) Notice of Assessment June 2013 DISCLAIMER: This document was originally drafted in French by the Institut national d'excellence en santé et en services sociaux (INESSS), and that version can be consulted at http://www.inesss.qc.ca/fileadmin/doc/INESSS/Analyse_biomedicale/Juin_2013/INESSS_Analyse_15.pdf http://www.inesss.qc.ca/fileadmin/doc/INESSS/Analyse_biomedicale/Juin_2013/INESSS_Analyse_16.pdf It was translated into English by the Canadian Agency for Drugs and Technologies in Health (CADTH) with INESSS’s permission. INESSS assumes no responsibility with regard to the quality or accuracy of the translation. While CADTH has taken care in the translation of the document to ensure it accurately represents the content of the original document, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the information in this document, the original document, or in any of the source documentation. 1 GENERAL INFORMATION 1.1 Requestor: Centre hospitalier universitaire de Québec (CHUQ). 1.2 Application Submitted: August 1, 2012. 1.3 Notice Issued: April 12, 2013. Note: This notice is based on the scientific and commercial information (submitted by the requestor[s]) and on a complementary review of the literature according to the data available at the time that this test was assessed by INESSS. 2 TECHNOLOGY, COMPANY, AND LICENCE(S) 2.1 Name of the Technology Reverse transcription of messenger RNA and amplification (RT-PCR).
    [Show full text]
  • Metastatic Tfe3-Overexpressing Renal Cell Carcinoma
    ISSN: 2378-3419 Ribeiro et al. Int J Cancer Clin Res 2021, 8:148 DOI: 10.23937/2378-3419/1410148 Volume 8 | Issue 2 International Journal of Open Access Cancer and Clinical Research CASe RePoRt Metastatic Tfe3-Overexpressing Renal Cell Carcinoma: Case Report and Literature Review Paulo Victor Zattar Ribeiro1, Leonora Zozula Blind Pope2, Beatriz Granelli1, Milena Luisa Schulze1*, Andréa Rodrigues Cardovil Pires3 and Mateus da Costa Hummelgen1 1University of Joinville’s Region, UNIVILLE, Brazil 2Dona Helena Hospital, Blumenau Street, Brazil Check for 3Diagnostic Medicine Fonte, São Sebastião, Brazil updates *Corresponding author: Milena Luisa Schulze, Department of Medicine, University of Joinville’s Region, UNIVILLE, Paulo Malschitzki Street, 10 - Zona Industrial Norte, 89249-710 Joinville – SC, Brazil Abstract Introduction Background: Renal cell carcinoma (RCC) associated with Renal cell carcinoma (RCC) associated with Xp11.2 Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC) is a translocation/TFE3 gene fusion (Xp11.2 RCC) is a rare rare subtype of RCC which is delineated as a distinct entity subtype of RCC which is delineated as a distinct enti- in the 2004 World Health Organization renal tumor classi- fication. ty in the 2004 World Health Organization renal tumor classification. Its morphology and clinical manifesta- Objective: To highlight a rare case, with few publications tions often overlap with those of conventional RCCs [1]. on the topic, in addition to providing scientific explanations about it. Children are more affected by this subtype than adults, accounts for 20-40% of pediatric RCC and 1-1.6% of RCC Method: This is a case report of a 58-year-old white male with the diagnosis of renal clear cell carcinoma (RCC).
    [Show full text]
  • Epigenetic Alterations of Chromosome 3 Revealed by Noti-Microarrays in Clear Cell Renal Cell Carcinoma
    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 735292, 9 pages http://dx.doi.org/10.1155/2014/735292 Research Article Epigenetic Alterations of Chromosome 3 Revealed by NotI-Microarrays in Clear Cell Renal Cell Carcinoma Alexey A. Dmitriev,1,2 Evgeniya E. Rudenko,3 Anna V. Kudryavtseva,1,2 George S. Krasnov,1,4 Vasily V. Gordiyuk,3 Nataliya V. Melnikova,1 Eduard O. Stakhovsky,5 Oleksii A. Kononenko,5 Larissa S. Pavlova,6 Tatiana T. Kondratieva,6 Boris Y. Alekseev,2 Eleonora A. Braga,7,8 Vera N. Senchenko,1 and Vladimir I. Kashuba3,9 1 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia 2 P.A. Herzen Moscow Oncology Research Institute, Ministry of Healthcare of the Russian Federation, Moscow 125284, Russia 3 Institute of Molecular Biology and Genetics, Ukrainian Academy of Sciences, Kiev 03680, Ukraine 4 Mechnikov Research Institute for Vaccines and Sera, Russian Academy of Medical Sciences, Moscow 105064, Russia 5 National Cancer Institute, Kiev 03022, Ukraine 6 N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow 115478, Russia 7 Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow 125315, Russia 8 Research Center of Medical Genetics, Russian Academy of Medical Sciences, Moscow 115478, Russia 9 DepartmentofMicrobiology,TumorandCellBiology,KarolinskaInstitute,17177Stockholm,Sweden Correspondence should be addressed to Alexey A. Dmitriev; alex [email protected] Received 19 February 2014; Revised 10 April 2014; Accepted 17 April 2014; Published 22 May 2014 Academic Editor: Carole Sourbier Copyright © 2014 Alexey A. Dmitriev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • TFE3 Antibody (C-Term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap18317b
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 TFE3 Antibody (C-term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP18317b Specification TFE3 Antibody (C-term) - Product Information Application WB,E Primary Accession P19532 Other Accession Q64092, Q05B92, NP_006512 Reactivity Human, Mouse Predicted Bovine Host Rabbit Clonality Polyclonal Isotype Rabbit Ig Calculated MW 61521 Antigen Region 489-516 TFE3 Antibody (C-term) - Additional Information TFE3 Antibody (C-term) (Cat. #AP18317b) western blot analysis in mouse kidney tissue Gene ID 7030 lysates (35ug/lane).This demonstrates the TFE3 Antibody detected the TFE3 protein Other Names (arrow). Transcription factor E3, Class E basic helix-loop-helix protein 33, bHLHe33, TFE3, BHLHE33 TFE3 Antibody (C-term) - Background Target/Specificity The microphthalmia transcription This TFE3 antibody is generated from factor/transcription rabbits immunized with a KLH conjugated synthetic peptide between 489-516 amino factor E (MITF-TFE) family of basic acids from the C-terminal region of human helix-loop-helix leucine zipper TFE3. (bHLH-Zip) transcription factors includes four family members: Dilution MITF, TFE3, TFEB and TFEC. The TEF3 protein WB~~1:1000 encoded by this gene activates transcription through binding to the Format muE3 motif of the Purified polyclonal antibody supplied in PBS immunoglobulin heavy-chain enhancer. The with 0.09% (W/V) sodium azide. This TFEC protein forms antibody is purified through a protein A heterodimers with the TEF3 protein and column, followed by peptide affinity inhibits TFE3-dependent purification. transcription activation. The TEF3 protein interacts with Storage transcription regulators such as E2F3, SMAD3, Maintain refrigerated at 2-8°C for up to 2 and LEF-1, and is weeks.
    [Show full text]
  • The Emerging Role of Ncrnas and RNA-Binding Proteins in Mitotic Apparatus Formation
    non-coding RNA Review The Emerging Role of ncRNAs and RNA-Binding Proteins in Mitotic Apparatus Formation Kei K. Ito, Koki Watanabe and Daiju Kitagawa * Department of Physiological Chemistry, Graduate School of Pharmaceutical Science, The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan; [email protected] (K.K.I.); [email protected] (K.W.) * Correspondence: [email protected] Received: 11 November 2019; Accepted: 13 March 2020; Published: 20 March 2020 Abstract: Mounting experimental evidence shows that non-coding RNAs (ncRNAs) serve a wide variety of biological functions. Recent studies suggest that a part of ncRNAs are critically important for supporting the structure of subcellular architectures. Here, we summarize the current literature demonstrating the role of ncRNAs and RNA-binding proteins in regulating the assembly of mitotic apparatus, especially focusing on centrosomes, kinetochores, and mitotic spindles. Keywords: ncRNA; centrosome; kinetochore; mitotic spindle 1. Introduction Non-coding RNAs (ncRNAs) are defined as a class of RNA molecules that are transcribed from genomic DNA, but not translated into proteins. They are mainly classified into the following two categories according to their length—small RNA (<200 nt) and long non-coding RNA (lncRNA) (>200 nt). Small RNAs include traditional RNA molecules, such as transfer RNA (tRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), PIWI-interacting RNA (piRNA), and micro RNA (miRNA), and they have been studied extensively [1]. Research on lncRNA is behind that on small RNA despite that recent transcriptome analysis has revealed that more than 120,000 lncRNAs are generated from the human genome [2–4].
    [Show full text]
  • The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Cell Rep Manuscript Author . Author manuscript; Manuscript Author available in PMC 2018 August 03. Published in final edited form as: Cell Rep. 2018 April 03; 23(1): 313–326.e5. doi:10.1016/j.celrep.2018.03.075. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma Christopher J. Ricketts1, Aguirre A. De Cubas2, Huihui Fan3, Christof C. Smith4, Martin Lang1, Ed Reznik5, Reanne Bowlby6, Ewan A. Gibb6, Rehan Akbani7, Rameen Beroukhim8, Donald P. Bottaro1, Toni K. Choueiri9, Richard A. Gibbs10, Andrew K. Godwin11, Scott Haake2, A. Ari Hakimi5, Elizabeth P. Henske12, James J. Hsieh13, Thai H. Ho14, Rupa S. Kanchi7, Bhavani Krishnan4, David J. Kwaitkowski12, Wembin Lui7, Maria J. Merino15, Gordon B. Mills7, Jerome Myers16, Michael L. Nickerson17, Victor E. Reuter5, Laura S. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). *Correspondence: [email protected]. SUPPLEMENTAL INFORMATION Supplemental Information includes six figures and four tables and can be found with this article online at https://doi.org/10.1016/ j.celrep.2018.03.075. AUTHOR CONTRIBUTIONS Conceptualization, C.J.R., P.T.S., W.K.R., and W.M.L.; Methodology, C.J.R., A.A.D., H.F., C.C.S., M.L., E.R., R. Bowlby, E.A.G., and A.G.R.; Investigation, C.J.R., A.A.D., H.F., C.C.S., M.L., E.R., R. Bowlby, E.A.G., S.H., R.S.K., B.K., W.L., H.S., B.G.V., A.G.R., W.K.R., and W.M.L.; Resources, A.A.D., R.A., R.
    [Show full text]
  • Atlas Journal
    Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Portal Teaching X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA Atlas Journal Atlas Journal versus Atlas Database: the accumulation of the issues of the Journal constitutes the body of the Database/Text-Book. TABLE OF CONTENTS Volume 3, Number 2, Apr-Jun 1999 Previous Issue / Next Issue Genes NONO (Xq12). Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (2): 133-136. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/NONOID168.html PRCC (papillary renal cell carcinoma) (1q21.2). François Desangles, Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (2): 137-140. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/PRCCID69.html PSF (PTB-associated splicing factor) (1p34). Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (2): 141-144. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/PSFID167.html PTCH1 (9q22.3) - updated. Jean-Loup Huret. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (2): 145-153. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/PTCH100.html TFE3 (transcription factor E3) (Xp11.2). Jean-Loup Huret, François Desangles. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (2): 154-160. [Full Text] [PDF] URL : http://AtlasGeneticsOncology.org/Genes/TFE3ID86.html HRAS (Harvey rat sarcoma viral oncogene homolog) (11p15.5). Franz Watzinger, Thomas Lion. Atlas Genet Cytogenet Oncol Haematol 1999; 3 (2): 161-172. [Full Text] [PDF] Atlas Genet Cytogenet Oncol Haematol 1999; 2 I URL : http://AtlasGeneticsOncology.org/Genes/HRASID108.html K-RAS (Kirsten rat sarcoma 2 viral oncogene homolog) (12p12).
    [Show full text]
  • Improved Detection of Gene Fusions by Applying Statistical Methods Reveals New Oncogenic RNA Cancer Drivers
    bioRxiv preprint doi: https://doi.org/10.1101/659078; this version posted June 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Improved detection of gene fusions by applying statistical methods reveals new oncogenic RNA cancer drivers Roozbeh Dehghannasiri1, Donald Eric Freeman1,2, Milos Jordanski3, Gillian L. Hsieh1, Ana Damljanovic4, Erik Lehnert4, Julia Salzman1,2,5* Author affiliation 1Department of Biochemistry, Stanford University, Stanford, CA 94305 2Department of Biomedical Data Science, Stanford University, Stanford, CA 94305 3Department of Computer Science, University of Belgrade, Belgrade, Serbia 4Seven Bridges Genomics, Cambridge, MA 02142 5Stanford Cancer Institute, Stanford, CA 94305 *Corresponding author [email protected] Short Abstract: The extent to which gene fusions function as drivers of cancer remains a critical open question. Current algorithms do not sufficiently identify false-positive fusions arising during library preparation, sequencing, and alignment. Here, we introduce a new algorithm, DEEPEST, that uses statistical modeling to minimize false-positives while increasing the sensitivity of fusion detection. In 9,946 tumor RNA-sequencing datasets from The Cancer Genome Atlas (TCGA) across 33 tumor types, DEEPEST identifies 31,007 fusions, 30% more than identified by other methods, while calling ten-fold fewer false-positive fusions in non-transformed human tissues. We leverage the increased precision of DEEPEST to discover new cancer biology. For example, 888 new candidate oncogenes are identified based on over-representation in DEEPEST-Fusion calls, and 1,078 previously unreported fusions involving long intergenic noncoding RNAs partners, demonstrating a previously unappreciated prevalence and potential for function.
    [Show full text]
  • SFPQ Rescues F508del-CFTR Expression and Function in Cystic
    www.nature.com/scientificreports OPEN SFPQ rescues F508del‑CFTR expression and function in cystic fbrosis bronchial epithelial cells Parameet Kumar1,5, Dharmendra Kumar Soni1,5, Chaitali Sen1, Mads B. Larsen2, Krystyna Mazan‑Mamczarz3, Yulan Piao3, Supriyo De3, Myriam Gorospe3, Raymond A. Frizzell2 & Roopa Biswas1,4* Cystic fbrosis (CF) occurs as a result of mutations in the cystic fbrosis transmembrane conductance regulator (CFTR) gene, which lead to misfolding, trafcking defects, and impaired function of the CFTR protein. Splicing factor proline/glutamine‑rich (SFPQ) is a multifunctional nuclear RNA‑binding protein (RBP) implicated in the regulation of gene expression pathways and intracellular trafcking. Here, we investigated the role of SFPQ in the regulation of the expression and function of F508del‑CFTR in CF lung epithelial cells. We fnd that the expression of SFPQ is reduced in F508del‑CFTR CF epithelial cells compared to WT‑CFTR control cells. Interestingly, the overexpression of SFPQ in CF cells increases the expression as well as rescues the function of F508del‑CFTR. Further, comprehensive transcriptome analyses indicate that SFPQ plays a key role in activating the mutant F508del‑CFTR by modulating several cellular signaling pathways. This is the frst report on the role of SFPQ in the regulation of expression and function of F508del‑CFTR in CF lung disease. Our fndings provide new insights into SFPQ‑mediated molecular mechanisms and point to possible novel epigenetic therapeutic targets for CF and related pulmonary diseases. Cystic fbrosis (CF) is a common life-limiting autosomal recessive genetic disease. Tis disease occurs as a result of mutations in the cystic fbrosis transmembrane conductance regulator (CFTR) gene.
    [Show full text]
  • Mouse Anti-Human Renal Cell Carcinoma Monoclonal Antibody, Clone JID768 (CABT-L2932) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Mouse Anti-Human Renal Cell Carcinoma monoclonal antibody, clone JID768 (CABT-L2932) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Product Overview This antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. Specificity Human Renal Cell Carcinoma Isotype IgG Source/Host Mouse Species Reactivity Human Clone JID768 Conjugate Unconjugated Applications IHC Reconstitution The prediluted antibody does not require any mixing, dilution, reconstitution, or titration; the antibody is ready-to-use and optimized for staining. The concentrated antibody requires dilution in the optimized buffer, to the recommended working dilution range. Positive Control Renal Cell Carcinoma Format Liquid Size Predilut: 7ml; Concentrate: 100ul, 1ml. Positive control slides also available. Buffer Predilute: Antibody Diluent Buffer Concentrate: Tris Buffer, pH 7.3 - 7.7, with 1% BSA Preservative <0.1% Sodium Azide Storage Store at 2-8°C. Do not freeze. Ship Wet ice Warnings This antibody is intended for use in Immunohistochemical applications on formalinfixed paraffin- 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved embedded tissues (FFPE), frozen tissue sections and cell preparations. BACKGROUND Introduction Renal Cell Carcinoma (RCC), also known as a gurnistical tumor, is a cancer of the kidney that arises from the proximal renal tubule; it is the most prevalent type of kidney cancer in adults. Anti-Renal Cell Carcinoma detects a glycoprotein in the brush border of the proximal renal tubule, and is a useful tool for diagnosis of primary renal cell carcinomas and metastatic renal cell carcinomas.
    [Show full text]
  • Research Article Epigenetic Alterations of Chromosome 3 Revealed by Noti-Microarrays in Clear Cell Renal Cell Carcinoma
    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 735292, 9 pages http://dx.doi.org/10.1155/2014/735292 Research Article Epigenetic Alterations of Chromosome 3 Revealed by NotI-Microarrays in Clear Cell Renal Cell Carcinoma Alexey A. Dmitriev,1,2 Evgeniya E. Rudenko,3 Anna V. Kudryavtseva,1,2 George S. Krasnov,1,4 Vasily V. Gordiyuk,3 Nataliya V. Melnikova,1 Eduard O. Stakhovsky,5 Oleksii A. Kononenko,5 Larissa S. Pavlova,6 Tatiana T. Kondratieva,6 Boris Y. Alekseev,2 Eleonora A. Braga,7,8 Vera N. Senchenko,1 and Vladimir I. Kashuba3,9 1 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia 2 P.A. Herzen Moscow Oncology Research Institute, Ministry of Healthcare of the Russian Federation, Moscow 125284, Russia 3 Institute of Molecular Biology and Genetics, Ukrainian Academy of Sciences, Kiev 03680, Ukraine 4 Mechnikov Research Institute for Vaccines and Sera, Russian Academy of Medical Sciences, Moscow 105064, Russia 5 National Cancer Institute, Kiev 03022, Ukraine 6 N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow 115478, Russia 7 Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow 125315, Russia 8 Research Center of Medical Genetics, Russian Academy of Medical Sciences, Moscow 115478, Russia 9 DepartmentofMicrobiology,TumorandCellBiology,KarolinskaInstitute,17177Stockholm,Sweden Correspondence should be addressed to Alexey A. Dmitriev; alex [email protected] Received 19 February 2014; Revised 10 April 2014; Accepted 17 April 2014; Published 22 May 2014 Academic Editor: Carole Sourbier Copyright © 2014 Alexey A. Dmitriev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • SFPQ and NONO Suppress RNA:DNA-Hybrid-Related Telomere
    ARTICLE https://doi.org/10.1038/s41467-019-08863-1 OPEN SFPQ and NONO suppress RNA:DNA-hybrid- related telomere instability Eleonora Petti1,2,6, Valentina Buemi1,2, Antonina Zappone1,2, Odessa Schillaci1, Pamela Veneziano Broccia1,2, Roberto Dinami1,2,6, Silvia Matteoni 3, Roberta Benetti4,5 & Stefan Schoeftner1,2 In vertebrates, the telomere repeat containing long, non-coding RNA TERRA is prone to form RNA:DNA hybrids at telomeres. This results in the formation of R-loop structures, replication 1234567890():,; stress and telomere instability, but also contributes to alternative lengthening of telomeres (ALT). Here, we identify the TERRA binding proteins NONO and SFPQ as novel regulators of RNA:DNA hybrid related telomere instability. NONO and SFPQ locate at telomeres and have a common role in suppressing RNA:DNA hybrids and replication defects at telomeres. NONO and SFPQ act as heterodimers to suppress fragility and homologous recombination at telo- meres, respectively. Combining increased telomere fragility with unleashing telomere recombination upon NONO/SFPQ loss of function causes massive recombination events, involving 35% of telomeres in ALT cells. Our data identify the RNA binding proteins SFPQ and NONO as novel regulators at telomeres that collaborate to ensure telomere integrity by suppressing telomere fragility and homologous recombination triggered by RNA:DNA hybrids. 1 Genomic Stability Unit, Laboratorio Nazionale—Consorzio Interuniversitario per le Biotecnologie (LNCIB), Padriciano 99, 34149 Trieste, Italy. 2 Department of Life Sciences, Università degli Studi di Trieste, Via E. Weiss 2, 34127 Trieste, Italy. 3 Cellular Networks and Molecular Therapeutic Targets, Proteomics Unit, IRCCS—Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144 Rome, Italy.
    [Show full text]